Arm Holdings plc - American Depositary Shares (ARM)

New stores are outperforming by $200,000 per location while sourcing gains protect margins, creating a dual growth engine.

The stock has struggled due to the bad housing market.

Palantir has rallied impressively in recent months, and its upcoming report could give the stock another boost.

It's starting to feel like this ticker might never stop falling.

SpaceX's growth is impressive, but its valuation leaves little room for disappointment.

Alphabet’s chip business is just starting to contribute to results.

How much of the Claude maker's rent goes to the chip giant?

Arm commands premium valuations on its licensing dominance, while Western Digital trades at a steep discount due to the industry's cyclical nature.

The banking giant is still pretty skeptical about Bitcoin.

Brazil stocks tumbled on election news, though not much is changing after the result.

The medication, which is being developed with the company's Chinese partner, did very well in a late-stage clinical trial.

Astrazeneca (NYSE:AZN) highlighted new clinical data across bladder, lung and gastric cancers at its ESMO 2026 investor event, including four presidential presentations that executives said support the company’s oncology growth strategy. Dave Fredrickson, executive vice president of the company’s o

Xencor (NASDAQ:XNCR) reported updated Phase 1 dose-expansion results for its ENPP3-targeting CD3 T-cell engager, XmAb819, in previously treated advanced clear cell renal cell carcinoma at the ESMO 2026 conference. The company said it selected a 400 microgram-per-kilogram intravenous target dose for

Dogecoin Labs aims to make the world's first meme coin more useful.

The satellite business model lets Eni expand clean energy without straining core capital allocation.

SpaceX's AI spending plans could translate into $400 billion in revenue for Nvidia next year.

It's a red flag investors would rather not see waving, but most of them may not have put this shift in its proper perspective.

Moderna (NASDAQ:MRNA) presented Phase 3 results for intismeran, its individualized neoantigen therapy, in combination with Merck’s pembrolizumab for patients with resected high-risk melanoma. The INTerpath-001 trial met its primary endpoint of relapse-free survival and a key secondary endpoint of di

Five consumer companies, five dividend checks, and five projects that will matter more in 2031 than they do today.

Sea Limited is entering the cloud business and is considering spinning off its fintech segment.

Intel can deliver stronger-than-expected results and guidance when it releases its Q3 earnings report on Oct. 29.

This company is entering a massive growth business, but investors didn't want to hear it.

Vera Therapeutics (NASDAQ:VERA) reported final efficacy results from its Phase III ORIGIN trial evaluating atacicept, marketed as TRUTAKNA, in adults with IgA nephropathy. The company presented the data at the American Society of Nephrology’s Kidney Week meeting in Denver, alongside publication in T

Fee-based federal hubs let NextEra capture data center demand without loading its balance sheet with capital.

Sandisk's shares could get a nice shot in the arm after the company's upcoming earnings report.